Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

OBJECTIVE: To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. METHODS: Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzi, Susan, Sánchez-Guerrero, Jorge, Merrill, Joan T, Furie, Richard, Gladman, Dafna, Navarra, Sandra V, Ginzler, Ellen M, D'Cruz, David P, Doria, Andrea, Cooper, Simon, Zhong, Z John, Hough, Douglas, Freimuth, William, Petri, Michelle A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465857/
https://www.ncbi.nlm.nih.gov/pubmed/22550315
http://dx.doi.org/10.1136/annrheumdis-2011-200831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465857/
https://www.ncbi.nlm.nih.gov/pubmed/22550315
http://dx.doi.org/10.1136/annrheumdis-2011-200831

Ejemplares similares